ArriVent BioPharma, Inc. Common Stock vs. Johnson & Johnson
Johnson & Johnson (JNJ) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| AVBP | JNJ | |
|---|---|---|
| Market Cap | $1.40 billion | $609.54 billion |
| Revenue (TTM) | — | $97.93 billion |
| Net Income (TTM) | $-163,735,000 | $21.04 billion |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| AVBP | JNJ | |
|---|---|---|
| P/E Ratio | — | 29.56 |
| Price / Book | 3.83 | 7.17 |
| Price / Sales | — | 6.22 |
AVBP leads on 1 of 1 valuation factors.
Profitability
| AVBP | JNJ | |
|---|---|---|
| Net Margin | — | 21.48% |
| Return on Equity | -44.63% | 24.76% |
JNJ leads on 1 of 1 profitability factors.
Dividend
| AVBP | JNJ | |
|---|---|---|
| Dividend Yield | — | 2.10% |
| Payout Ratio | — | 62.18 |
AVBP and JNJ split the dividend factors evenly.
Risk & Sentiment
| AVBP | JNJ | |
|---|---|---|
| Short Interest | 0.04% | 0.67% |
AVBP leads on 1 of 1 risk & sentiment factors.
Dig deeper: AVBP overview, AVBP financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.